Taylor & Francis Group
Browse
kepi_a_1954780_sm4517.pptx (59.22 MB)

Loss of KMT2C reprograms the epigenomic landscape in hPSCs resulting in NODAL overexpression and a failure of hemogenic endothelium specification

Download (59.22 MB)
presentation
posted on 2021-07-25, 03:20 authored by Shailendra Maurya, Wei Yang, Minori Tamai, Qiang Zhang, Petra Erdmann-Gilmore, Amelia Bystry, Fernanda Martins Rodrigues, Mark C. Valentine, Wing H Wong, Reid Townsend, Todd E. Druley

Germline or somatic variation in the family of KMT2 lysine methyltransferases have been associated with a variety of congenital disorders and cancers. Notably, KMT2A-fusions are prevalent in 70% of infant leukaemias but fail to phenocopy short latency leukaemogenesis in mammalian models, suggesting additional factors are necessary for transformation. Given the lack of additional somatic mutation, the role of epigenetic regulation in cell specification, and our prior results of germline KMT2C variation in infant leukaemia patients, we hypothesized that germline dysfunction of KMT2C altered haematopoietic specification. In isogenic KMT2C KO hPSCs, we found genome-wide differences in histone modifications at active and poised enhancers, leading to gene expression profiles akin to mesendoderm rather than mesoderm highlighted by a significant increase in NODAL expression and WNT inhibition, ultimately resulting in a lack of in vitro hemogenic endothelium specification. These unbiased multi-omic results provide new evidence for germline mechanisms increasing risk of early leukaemogenesis.

Funding

This work was supported by the National Cancer Institute [P30 CA091842]; National Institute of General Medical Sciences [P41 GM103422]; Eli Seth Matthews Leukemia Foundation; Kellsie’s Hope Foundation; Institute for Clinical and Translational Research, Washington University School of Medicine (US) [NCATS UL1 TR000448].

History